A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

October 9, 2019

Study Completion Date

October 10, 2019

Conditions
Scleroderma, Systemic
Interventions
DRUG

Microgynon

fixed sequence trial

DRUG

Nintedanib

fixed sequence trial

Trial Locations (10)

9000

UNIV UZ Gent, Ghent

69126

Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg

75018

HOP Bichat, Paris

91054

Universitätsklinikum Erlangen, Erlangen

93009

HOP Avicenne, Bobigny

6525 GL

Radboud Universitair Medisch Centrum, Nijmegen

2801-951

Hospital Garcia de Orta, EPE, Almada

2720-276

Hospital Fernando Fonseca, EPE, Amadora

08026

Hospital Santa Creu i Sant Pau, Barcelona

08035

Hospital Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03675581 - A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) | Biotech Hunter | Biotech Hunter